How do you sequence systemic therapies for recurrent/metastatic head/neck cancer following the recent approval of pembrolizumab?

We currently do not have any available predictive biomarker to inform us on which patients will respond to PD-1 inhibitors based on recently presented data. This work remains investigational. Hence, we do not check PD-1 status to determine whether or not patients should receive immunotherapy.